Suggestions
Leighanne Oh
Life Sciences Investor
Leighanne Oh is a prominent biotech investor currently working at Ascenta Capital, having previously held a position as a biotech investor at Sofinnova Investments from 2019 to 2022. Her role at Sofinnova involved private equity investing in early- to late-stage biotech companies, as well as working on a therapeutics long/short equity public team in 2019. Sofinnova Investments is known for its focus on life sciences, particularly therapeutic drugs, and manages approximately $3.0 billion in assets.1
Education and Early Career
Leighanne holds both a Bachelor of Science in Engineering (B.S.E.) in Biomedical Engineering and a Master of Science (M.S.) in Biomedical Engineering from Duke University, where she was a Bill and Melinda Gates Millennium Scholar. Her academic research included work at Michael Lynch's lab at Duke.1
Before her tenure at Sofinnova, she worked as a Healthcare Investment Banking Analyst at Jefferies and had experience in various roles, including as an Advanced Manufacturing/Operations Engineer at GE Healthcare and a Research Analyst at NASA Langley Research Center.1
Professional Affiliations
In addition to her investment roles, Leighanne is actively involved in the biotech community and serves on the Galien Advisory Board, contributing to discussions and initiatives in the life sciences sector.2
Highlights
The Breaking7% National Summit is convening in San Diego! We are excited to bring together B7% women across all the cities over several days to have candid conversations, make connections, and build relationships
Please indicate your interest by filling out this form here! https://lnkd.in/ecQUgjfE
About Breaking7% (B7%): B7% originally started in Boston and expanded to NYC, SD, SF, and Europe. B7% aims to build impactful connections and relationships among women in business decision-making roles to grow deal flow, partnerships, and information access within the network. We do this by providing intimate dinner settings for women in venture and BD roles to connect through several initiatives
Magdalena Tyrpien Sarah Soo-Hoo Jeni Lee Helen Siaw Michelle Levine Pascal Krotee, Ph.D. Rachel Tsunemoto Hislop, PhD Chanie Howard Lulu X. Tiffany Yu Angel Martin Amanda Chen
Day 3 of 4 | London Science & Industry Day
Thank you LocalGlobe and Ferdinando Sigona for hosting us last week! I was just amazed to learn about #PhoenixCourt and the richness of innovation in this area.
My key takeaway is realizing that the London ecosystem is a powerful cluster driving diverse clinical trials and drug approvals:
- From 2015-2020, the life sciences ecosystem in London supported 5K+ commercial clinical trials and recruited 43K patients
- Cancer Research UK (CRUK) has developed 11 marketed drugs and is #2 in largest oncology out-licensor globally, leading to 17 exited companies and £2.9B in capital raised +The Cell and Gene Therapy Catapult in 2022 supported 44 Phase III clinical trials and ten approved therapies.
Thank you to all! The Francis Crick Institute, Cancer Research UK (CRUK), The Alan Turing Institute, Health Data Research UK (HDR UK), Cell and Gene Therapy Catapult Hilary Shannon
